MedWatch

New Leo Pharma-drug gains EU approval

The European Commission has approved a new drug from the Danish company Leo Pharma for the European market.

50,000 Danes could be looking forward to new treatment to prevent the development of skin cancer after the EU Commission has approved Leo Pharma’s drug Picato for marketing in the EU, the company announces.

The drug is aimed at patients suffering from solar keratosis, also known as actinic keratosis, a disease that affects some 50,000 Danes yearly, according to professor and dermatologist at Bispebjerg Hospital, Hans Christian Wulf.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier